Sunshine Guojian Pharmaceutical(Shanghai) Co.Ltd(688336)
2021 environmental, social and Corporate Governance Report
catalogue
1. Walk into Sunshine Guojian Pharmaceutical(Shanghai) Co.Ltd(688336) three
1.1 about us three
1.2 ESG Management four
2. Continuously improve the level of corporate governance eight
2.1 good corporate governance structure eight
2.2 compliance operation 11 3. Long term pioneer of health industry fifteen
3.1 R & D layout and achievements fifteen
3.2 consolidate innovation and R & D capability seventeen
3.3 join hands with the industry for common development nineteen
4. Reliable provider of antibody drugs twenty-one
4.1 continuously improving quality management ability twenty-one
4.2 build the sustainable development capacity of supply chain twenty-eight
4.3 provide high-quality services for customers and patients 30 5. The creator of social shared value thirty-three
5.1 inclusive and efficient workplace environment thirty-three
5.2 improve the accessibility of antibody drugs 39 6. Actors of green power forty-two
6.1 environmental management system forty-two
6.2 addressing climate change forty-four
6.3 reduce pollutant emission 48 7. Data section 49 8. Benchmarking index 54 9. Report preparation instructions 571. Walk into Sunshine Guojian Pharmaceutical(Shanghai) Co.Ltd(688336) 11 about us
Sunshine Guojian Pharmaceutical(Shanghai) Co.Ltd(688336) Pharmaceutical (Shanghai) Co., Ltd., founded in 2002, is the first batch of innovative biomedical high-tech enterprises focusing on antibody drugs in China. It has developed into a pioneer of antibody drugs in China with independent R & D, industrialization and commercialization capabilities. Taking innovative therapeutic antibody drugs as the main research and development direction, the company’s technical ability covers the whole process of antibody drug research and development, prospectively constructs multiple technical platforms of innovative antibody drugs, and has the systematic innovation ability from drug discovery, preclinical research, pilot process development, quality research, clinical research to industrialization, so as to provide high-quality and Safe and effective clinical solutions.
At present, the company has a National Engineering Research Center for antibody drugs, operates the leading antibody drug production base of China’s biopharmaceutical companies, has listed three therapeutic antibody drugs, and has built a bioreactor with a total scale of more than 40000 liters. \uf09f Company Name: Sunshine Guojian Pharmaceutical(Shanghai) Co.Ltd(688336) Pharmaceutical (Shanghai) Co., Ltd
\uf09f English Name: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd
\uf09f date of establishment: 2002 \uf09f listing status: Shanghai Stock Exchange science and Innovation Board (listing Code: Sunshine Guojian Pharmaceutical(Shanghai) Co.Ltd(688336) . SH) \uf09f headquarters address: Shanghai, China \uf09f total number of employees: 1278 key contribution performance in 2021
“Benefit + hope” Bethune ISEP public welfare donation project benefited 20733 patients with 9.7576 million yuan and 65724 drugs
Public welfare investment “inclusive life” Bethune septin public welfare donation project benefited 1405 patients and 10821 drugs
50.96% 27.70% 100%
Proportion of R & D investment proportion of R & D personnel proportion of total employees employee training coverage
16.6h 21，410.73 100%
Per capita training time of employees is long, and tons of carbon dioxide equivalent pollutants are discharged up to standard
Greenhouse gas emissions (category I)
(II)
1.2 ESG management
Adhering to the concept of “cherishing life, paying attention to survival and creating life”, Sunshine Guojian Pharmaceutical(Shanghai) Co.Ltd(688336) ESG management focuses on four areas, including becoming a long-term pioneer of health industry, a reliable provider of antibody drugs, a creator of social shared value and an actor of green power.
Sunshine Guojian Pharmaceutical(Shanghai) Co.Ltd(688336) is committed to becoming an innovative therapeutic antibody drug company benefiting China and facing the world. It continues to innovate and develop, adheres to excellent quality management and stable operation, provides stable and reliable antibody drugs, and contributes to the high-quality development of the health industry. We actively implement the corporate mission of “making innovative antibody drugs within reach”, create shared value for all parties in society and help build a healthy China while realizing our own development. ESG Management Architecture
The company has established a top-down ESG management structure to effectively promote ESG work. The board of directors coordinates the management of the company’s ESG matters and ensures the company’s efficient decision-making on all ESG work. The company’s board of directors has set up an ESG working group as the implementation layer of ESG work, led by the brand public relations department, which is responsible for coordinating the company’s ESG work, carrying out information communication and disclosure, assessing the company’s ESG related risks and promoting all functional departments to actively implement ESG related work. ESG management strategy
While achieving our own compliant operation and steady growth, we identify four ESG key areas related to our own operation and development, and actively plan the company’s ESG strategies and key actions.
The long-term prescription of antibody drugs in the health industry is reliable, providing social shared value and creating green power
Tuozhe
Sunshine Guojian Pharmaceutical(Shanghai) Co.Ltd(688336) ‘s actions and contributions
\uf09f create efficient innovation \uf09f build quality control \uf09f respect and protect employees \uf09f build a perfect environment
Develop a new R & D platform, improve the management system, strengthen the legitimate rights and interests of production, control the environment management system and save energy
Innovate the management of R & D capability product testing and inspection, reasonably use staff promotion resources, and reduce self-reliance
\uf09f strengthen intellectual property management, improve the development path of quality management and stimulate the environment generated by fuselage operation
Protection capacity system to create an inclusive and efficient burden
\uf09f contribute to the development of the industry \uf09f identify and control the workplace environment provided \uf09f identify climate change
Contribute to the risk chain and actively fight \uf09f carry out risk management through daily protection of risks and opportunities
Measures for sustainable development of supply chain, occupational disease risk and global climate change mitigation
Develop ability and effectively ensure actions such as identification and employee training
The quality and supply mode of products ensure the health of employees
\uf09f health and safety through customer service
System and customer privacy protection\uf09f through reasonable
Care, responsible marketing, equivalence, public welfare medicine donation
The way is for customers and patients, rural revitalization
Provide high-quality service and improve antibody drugs
Accessibility of
Communication with interested parties and analysis of substantive issues
The sustainable development of the company is inseparable from the trust and support of all stakeholders.
Sunshine Guojian Pharmaceutical(Shanghai) Co.Ltd(688336) communicate with stakeholders through information disclosure of listed companies, official website and other channels, build an effective communication mechanism and establish close contact with stakeholders. The company actively listens to and responds to the demands of major stakeholders, including shareholders / investors, employees, customers and patients, suppliers, partners, governments and regulators.
Issues concerned by stakeholders and communication channels
Communication and response to issues concerned by stakeholders
Compliance operation, business ethics, information disclosure of listed companies, shareholders
Shareholders / investors’ character, quality and safety, innovation and R & D conference, investor meeting
And health accessibility
Communication and response to issues concerned by stakeholders
Product quality and safety, employee rights
Employee benefits and welfare, human capital development union and workers’ Congress, regular training exhibition, intellectual property protection, customer assessment and promotion
Information and privacy protection
Compliance operation, business ethics, production quality management system, standardizing the quality and safety of drug customers and patients, and customer information training
And privacy protection
Compliance operation, product quality and safety
Supplier wide, intellectual property protection, emission regulation, supplier management system, transparent management, sustainable and fair procurement of supply chain, collaborative development management, community and public welfare
Partners (hospitals, industry associations, product quality and safety, customer information quality management system, compliance system meeting, academic organizations, etc.) information and privacy protection, compliance economy and compliance culture construction
Business ethics
Compliance operation, business ethics, construction and management of production compliance system, product quality and safety of government and regulatory agencies, intellectual property protection, quality management body protection, customer information and privacy protection system, and various public welfare projects
Protection, community and public welfare
In 2021, based on national policies and industry hotspots and benchmarking regulatory requirements, the company carried out a survey on substantive issues of stakeholders this year, identified high substantive issues for the company, such as “product quality management”, “business ethics”, “compliant operation”, “innovative R & D and health accessibility” and “human capital development”, and made key disclosure in the report to better respond to the demands and expectations of stakeholders.
Preliminary identification of topics and comprehensive analysis of stakeholder communication results
Analyze the national macro policies and the bank’s cooperation with internal and external stakeholders, and construct the essence according to the evaluation results
Industry hotspot content exhibition communication, including shareholder / investment topic analysis matrix, combined with
Sort out and analyze the importance of Shanghai Securities Exchange, employees, customers and patients and topics,
The ranking results of the topics obtained by the listed companies on the E-TECH innovation board from suppliers, partners and governments,
Guidelines for the use of legal and regulatory rules, the second government and regulatory agencies, etc., recover the high substantive issues in the report
No. – 85 questionnaires of voluntary information disclosure, of which the effective questions focus on disclosure.
47 volumes of “about doing a good job in the listing of science and Innovation Board”
The 2021 annual report of the company is based on the opinions of stakeholders,
And other policies, combined with experts’ substantive comments on the topic
And standards
The analysis of the company’s strategy and practice focuses on the evaluation and evaluation of stakeholders
Identify the impact of 17 issues on decision-making and Sunshine Guojian Pharmaceutical(Shanghai) Co.Ltd(688336)
Impact on economy, environment and society
The importance of two dimensions
